Edition:
United Kingdom

Idorsia Ltd (IDIA.S)

IDIA.S on Swiss Exchange

20.66CHF
26 Jun 2019
Change (% chg)

-- (--)
Prev Close
CHF20.66
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
280,818
52-wk High
CHF27.86
52-wk Low
CHF15.20

Latest Key Developments (Source: Significant Developments)

Idorsia Q1 US GAAP Net Loss Widens To CHF 106 Mln
Thursday, 18 Apr 2019 

April 18 (Reuters) - Idorsia Ltd ::IDORSIA ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER 2019.US GAAP OPERATING EXPENSES IN Q1 2019 AT CHF 125 MILLION.NON-GAAP OPERATING EXPENSES IN Q1 2019 AT CHF 117 MILLION.UNCHANGED GUIDANCE FOR 2019.Q1 US GAAP NET LOSS AMOUNTED TO CHF 106 MILLION COMPARED TO CHF 79 MILLION.  Full Article

Idorsia FY US GAAP Operating Expenses At CHF 432 Mln
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - IDORSIA LTD ::US GAAP OPERATING EXPENSES 2018 AT CHF 432 MILLION.NON-GAAP OPERATING EXPENSES 2018 AT CHF 399 MILLION, INCLUDING CHF 15.NON-GAAP OPERATING EXPENSES 2018 AT CHF 399 MILLION, INCLUDING CHF 15 MILLION MILESTONE PAYMENT TO REVERAGEN, IN LINE WITH 2018 GUIDANCE.SAYS GUIDANCE FOR 2019: US-GAAP OPERATING EXPENSES OF AROUND CHF 570 MILLION AND.SAYS FULL YEAR 2018, US GAAP NET LOSS AMOUNTED TO CHF 386 MILLION COMPARED TO CHF 14 MILLION FOR PERIOD ENDING DECEMBER 31, 2017..SAYS INCREASE OF NET LOSS WAS MAINLY DRIVEN BY LOWER REVENUES AND HIGHER OPERATING COSTS.AT END OF 2018, IDORSIA'S LIQUIDITY (INCLUDING CASH, CASH EQUIVALENTS, SHORT- AND LONG-TERM DEPOSITS) AMOUNTED TO CHF 1,220 MILLION..SAYS ALL LATE-STAGE TRIALS ARE NOW INITIATED, WITH DATA EXPECTED TO BE REPORTED IN 2020 AND 2021.SAYS MAKING 'GREAT PROGRESS' WITH EARLY-STAGE COMPOUNDS BY ACCUMULATING INFORMATION ON CLINICAL PHARMACOLOGY IN HEALTHY VOLUNTEERS OR CONDUCTING PHASE 2 PROFILING IN PATIENTS.SAYS CHF 505 MILLION RAISED IN JULY 2018 SHOULD GIVE IDORSIA NECESSARY LEEWAY TO ASSESS CLINICAL DATA FOR OUR LATE-STAGE PIPELINE AND THEN MAKE APPROPRIATE STRATEGIC DECISIONS REGARDING COMMERCIALIZATION.  Full Article

Santhera Calls EGM And Proposes Ordinary Share Capital Increase
Tuesday, 20 Nov 2018 

Nov 20 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG ::SANTHERA CALLS EXTRAORDINARY GENERAL MEETING AND PROPOSES ORDINARY SHARE CAPITAL INCREASE TO RAISE APPROXIMATELY CHF 50 MILLION.CAPITAL INCREASE TO BE EFFECTED BY WAY OF AN ACCELERATED BOOK BUILDING.CAPITAL INCREASE TO FINANCE INITIAL PAYMENT OF USD 20 MILLION TO IDORSIA FOR RIGHTS TO VAMOROLONE.CAPITAL INCREASE ALSO TO FINANCE DEVELOPMENT OF VAMOROLONE AND TO FUND ITS ONGOING ACTIVITIES.WILL ISSUE 1,000,000 NEW REGISTERED SHARES TO IDORSIA FROM ITS EXISTING AUTHORIZED CAPITAL.  Full Article

Santhera Enters Into Agreement To Buy Option From Idorsia For Exclusive Sub-License Of First-In-Class Dissociative Steroid Vamorolon
Tuesday, 20 Nov 2018 

Nov 20 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG ::SANTHERA ENTERS INTO AGREEMENT TO ACQUIRE OPTION FROM IDORSIA FOR EXCLUSIVE SUB-LICENSE OF FIRST-IN-CLASS DISSOCIATIVE STEROID VAMOROLON.IDORSIA TO BECOME LARGEST SHAREHOLDER IN SANTHERA WITH A 13.3% EQUITY STAKE.  Full Article

Idorsia Maintains Collaboration Agreement With Reveragen
Monday, 5 Nov 2018 

Nov 5 (Reuters) - Idorsia Ltd ::MAINTAINS COLLABORATION AGREEMENT WITH REVERAGEN.FOLLOWING RECEIPT OF CLINICAL STUDY REPORT FOR PHASE 2A STUDY WITH VAMOROLONE, WILL PAY REVERAGEN USD 15 MILLION TO MAINTAIN AGREEMENT.  Full Article

Idorsia Says Representative Of Former Axovan Shareholders Filed Complaint Against Actelion
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - IDORSIA LTD ::SAYS REPRESENTATIVE OF FORMER AXOVAN SHAREHOLDERS CLAIMS DEMERGER OF ACTELION AND IDORSIA WOULD TRIGGER ACCELERATION OF ALL OUTSTANDING MILESTONE PAYMENTS FOR CLAZOSENTAN.SAYS REPRESENTATIVE OF FORMER AXOVAN SHAREHOLDERS HAS FILED A COMPLAINT AGAINST ACTELION.BELIEVES THAT SUCH CLAIM HAS NO MERIT.  Full Article

Idorsia 9Mth US GAAP Net Loss Of CHF 278 Mln
Tuesday, 23 Oct 2018 

Oct 23 (Reuters) - IDORSIA LTD ::US GAAP OPERATING RESULTS IN 9M 2018: LOSS OF CHF 271 MILLION.NON-GAAP* OPERATING RESULTS 9M 2018: LOSS OF CHF 247 MILLION.UNCHANGED GUIDANCE FOR 2018: NON-GAAP OPERATING EXPENSES OF AROUND CHF 390 MILLION.9MTH US GAAP NET LOSS AMOUNTED TO CHF 278 MILLION.  Full Article

Idorsia Launches Offering Of New Shares And Convertible Bonds
Tuesday, 10 Jul 2018 

July 10 (Reuters) - Idorsia Ltd ::IDORSIA LAUNCHES THE OFFERING OF NEW SHARES IN COMBINATION WITH THE OFFERING OF CONVERTIBLE BONDS TO FUND THE DEVELOPMENT OF ITS ADVANCING PIPELINE.LAUNCHES OFFERING OF UP TO 11,912,000 NEW SHARES THROUGH AN ACCELERATED BOOKBUILDING PROCESS.OFFERING OF CHF 200 MILLION CONVERTIBLE BONDS.NET PROCEEDS WILL ALLOW TO FUND PHASE 3 DEVELOPMENT OF IDORSIA'S LATE-STAGE PIPELINE.BONDS WILL HAVE A MATURITY OF 6 YEARS.BONDS WILL BE OFFERED WITH A COUPON BETWEEN 0.50% AND 1.00%.BONDS WILL BE OFFERED WITH CONVERSION PREMIUM BETWEEN 30% AND 35% ABOVE BOOKBUILDING PRICE OF OFFER SHARES.  Full Article

Idorsia Initiates Precision - Phase 3 Study With Aprocitentan
Wednesday, 20 Jun 2018 

June 20 (Reuters) - Idorsia Ltd ::IDORSIA INITIATES PRECISION - PHASE 3 STUDY WITH APROCITENTAN FOR RESISTANT HYPERTENSION MANAGEMENT.  Full Article

Idorsia Starts Phase 3 Registration Study To Assess Lucerastat As Potential New Treatment Option For Patients With Fabry Disease
Wednesday, 16 May 2018 

May 16 (Reuters) - IDORSIA LTD ::IDORSIA INITIATES MODIFY, A PHASE 3 REGISTRATION STUDY TO ASSESS LUCERASTAT AS A POTENTIAL NEW TREATMENT OPTION FOR PATIENTS WITH FABRY DISEASE.  Full Article

UPDATE 1-Idorsia confirms 2019 spending plan as clinical trials "on track"

ZURICH, April 18 Swiss biotech Idorsia said on Thursday that all four clinical trials of its late-stage drug hopefuls were "on track" as it confirmed expectations of spending 570 million Swiss francs ($564 million) in the current year on the projects.